

13th Antibody Industrial Symposium 2025 June 25-26, 2025 – Tours www.aiscongress.com

Abstract Submission Guidelines to the Scientific Pitch

In order to provide visibility and promote innovation in the field of *Therapeutic Antibodies*, *Recombinant Proteins and other innovative biotherapeutics for fighting Diseases*, a call is open on for abstract submission for:

- a **Pitch presentation** of 10min at the session "Innovative Approaches and New trend Technologies" that will be held on Wednesday 25th June 2025;
- a Poster presentation at the poster session.

These are great opportunities for academic laboratories and companies to share their new research work!

The AIS2025 Scientific Committee will review the abstracts for innovative products, technology and research.

All submissions must be non-promotional. Abstracts containing commercial products, technologies or services must provide competitive context, and show no commercial bias.

Fill-in the Abstract From and send it to: ana-sofia.antunes@mabdesign.fr

Deadline for abstract submission: 4th April 2025

Notifications to the authors: 13th May 2025

The AIS2025 Organization will notify you via email whether your presentation has been accepted or not to give a pitch. If your abstract is accepted, you will have to register to the AIS2025 on the website **until 16**th **May 2025** if it has not been done before.

Evaluation Criteria

Eligible authors: Start-up, SMEs, companies or research laboratories that want to share an innovative project, product or technology related to Innovative Approaches / Technologies for fighting diseases.

Main topics: Therapeutic Antibodies (mAbs), ADCs, Fusion proteins, efficacity & safety, innovative technologies, drug discovery, AI, in silico, biomarkers, diagnostic, preclinical models, biological drugs characterization tools, analytical tools, real time analysis, bioproduction.

Selection criteria

The most successful abstracts will include new breakthrough technologies that can contribute to the new therapeutic approaches as well as new products/technologies that open a new vision for this field. Priority consideration will be given to abstracts that feature:

- an innovative character of the technology or therapeutic product
- a health/medical benefit associated
- a breakthrough research project that offers new ideas and opportunities in the field of immunomodulation
- projects that can engage the industrial sector and bring economic benefits
- Innovation that goes beyond traditional approaches.

Speaker responsibilities

Each presenter chosen is responsible for all expenses related to his/her participation in AIS2025 including registration, transportation and accommodation.

By submitting an abstract, you grant the organizers permission to publish the abstract in hard copy or in electronic/digital formats.

Abstract Format

Abstract Title (Bolded) -Calibri font, size 12

Title: The title should clearly define the content of the abstract.

Author(s): if concerned include the names of all contributing authors. <u>Underline the speaker's name</u>.

Author's affiliation: indicate postal address of the authors.

Example: First author's First Name First author's LAST NAME¹, Second author's First name second author's LAST NAME², etc

¹Department, Organization, Country

²Department, Organization, Country

Abstract (maximum 500 words)

Use only standard keyboard characters. Reduce abbreviations to a minimum, especially non-standard one, and define at first use. No tables or figures should be inserted into the abstract title or text.

Font & Size: Calibri font, size 11

Structure your abstract according to:

- -Background: describe the scientific or/and medical context that lead to your innovation.
- Offer/project description: describe your project, research or product. Include in your description its aims, its methodology and its benefits/solutions
- Innovative strength & Applications: explain the innovative asset and specificity of your offer from a scientific, medical, technical and economical point of view. Indicate its different applications.
- **Conclusion**: explain how your work contributes to the field of Immunomodulation with therapeutic antibodies.

Keywords: please provide 5 keywords that describe your presentation, its targets and the goals addressed.

Abstract should be **saved under the Authors Name (FirstName-LastName)** and in .docx format. No other format will be accepted.

Contact

For any enquiry please contact Ana Antunes (ana-sofia.antunes@mabdesign.fr).